家族性地中海熱治療薬の世界市場レポート 2025年

家族性地中海熱治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.5％で21億5,000万米ドルに成長します。予測期間に予測される成長は、先進的ながん治療オプションの採用増加、遺伝子治療や生物製剤への関心の高まり、先進的な治療法の使用増加、効果的な薬剤の利用率向上、支持療法の普及などの要因によるものです。この期間の主な動向としては、治療法の進歩、新薬クラスの導入、学術機関、研究機関、製薬企業間の連携、新治療法の採用、技術の発展などが挙げられます。

遺伝子治療の採用拡大が、家族性地中海熱（FMF）医薬品市場の成長を大きく後押しすると予想されます。遺伝子治療は、遺伝子レベルで病気を治療または予防するために、欠陥のある遺伝子を変更または置換する医療アプローチです。遺伝子治療の増加は、遺伝子工学の進歩によって促進されています。遺伝子工学は、遺伝的障害を正確に標的にし、修正することを可能にし、以前は治療不可能と考えられていた病態に潜在的な治療法を提供します。家族性地中海熱（FMF）の場合、遺伝子治療はMEFV（地中海熱）遺伝子の根本原因である変異をターゲットとするもので、単なる症状の管理ではなく、長期的あるいは永続的な治癒をもたらす可能性があります。例えば、2024年7月、米国の非営利団体である米国遺伝子細胞治療学会（ASGCT）は、2024年第2四半期に76件の遺伝子治療試験が開始され、前四半期から25％増加したと報告しました。その結果、遺伝子治療の増加がFMF医薬品市場の成長を牽引しています。

家族性地中海熱（FMF）医薬品市場の主要企業は、費用対効果の高いジェネリック代替品を含む先進治療の開拓に注力するとともに、新規の生物製剤や遺伝子治療薬の探索にも取り組んでいます。費用対効果の高いジェネリック医薬品とは、有効成分、用量、安全性、有効性が同じである先発医薬品の廉価版です。例えば、2022年1月、米国の医薬品製造会社であるキャンバー・ファーマシューティカルズ・インクは、コルクリス（コルヒチン）のジェネリック錠剤を発売し、製品ポートフォリオを拡大しました。この錠剤は、成人および4歳以上の小児のFMFの治療と予防、痛風の再燃の管理に使用されます。錠剤の強さは0.6mgで、30錠入りと100錠入りがあります。今回の発売は、患者ケアの向上のため、高品質で手頃な価格のジェネリック医薬品を提供するというキャンバーのコミットメントに沿ったものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界家族性地中海熱治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の家族性地中海熱治療薬市場：成長率分析
• 世界の家族性地中海熱治療薬市場の実績：規模と成長, 2019-2024
• 世界の家族性地中海熱治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界家族性地中海熱治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の家族性地中海熱治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルヒチン
• インターロイキン-1阻害剤
• 抗IL-6薬
• 世界の家族性地中海熱治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界の家族性地中海熱治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 臨床診断検査室
• その他のエンドユーザー
• 世界の家族性地中海熱治療薬市場コルヒチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口コルヒチン
• 静脈内コルヒチン
• 世界の家族性地中海熱治療薬市場インターロイキン-1阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アナキンラ
• カナキヌマブ
• リロナセプト
• 世界の家族性地中海熱治療薬市場抗IL-6薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トシリズマブ
• サリルマブ
• シルツキシマブ

第7章 地域別・国別分析

• 世界の家族性地中海熱治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の家族性地中海熱治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 家族性地中海熱治療薬市場：競合情勢
• 家族性地中海熱治療薬市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Swedish Orphan Biovitrum AB（Sobi）
• Granules Pharmaceuticals Inc.
• Sanmar Group
• Indena S.p.A.
• Harman Finochem
• Camber Pharmaceuticals Inc.
• R-Pharm Group
• Alchem International
• AdvaCare Pharma USA LLC
• ViennaLab Diagnostics GmbH
• Honour Lab Ltd.
• Vital Laboratories Pvt. Ltd.
• Enomark Biotech Pvt. Ltd.
• Gonane Pharma
• Ennature Biopharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 家族性地中海熱治療薬市場2029：新たな機会を提供する国
• 家族性地中海熱治療薬市場2029：新たな機会を提供するセグメント
• 家族性地中海熱治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Familial Mediterranean fever (FMF) pharmaceuticals refer to medications used to manage and treat FMF, a genetic disorder marked by recurrent episodes of fever and inflammation, often affecting the abdomen, chest, and joints. The primary goal of these medications is to reduce the frequency and severity of attacks and prevent long-term complications such as amyloidosis.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main pharmaceuticals used in the treatment of familial Mediterranean fever include colchicine, interleukin-1 inhibitors, and anti-IL-6 drugs. Colchicine is a medication that helps reduce inflammation and prevent flare-ups in conditions such as gout and other inflammatory disorders. It can be administered both orally and via injection and is utilized by various end users, including hospitals, clinical diagnostic laboratories, and other healthcare facilities.

The familial mediterranean fever pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides familial mediterranean fever pharmaceuticals market statistics, including familial mediterranean fever pharmaceuticals industry global market size, regional shares, competitors with a familial mediterranean fever pharmaceuticals market share, detailed familial mediterranean fever pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the familial mediterranean fever pharmaceuticals industry. This familial mediterranean fever pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The familial mediterranean fever pharmaceuticals market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth observed in the historic period can be attributed to factors such as the increasing prevalence of the disease, higher migration rates, a growing geriatric population, a rise in genetic abnormalities within the MEFV gene, and an increase in genetic mutations.

The familial mediterranean fever pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth projected for the forecast period can be attributed to factors such as the increased adoption of advanced cancer therapeutic options, growing interest in gene therapy and biologics, a rise in the use of advanced therapies, higher utilization of effective medications, and the widespread adoption of supportive therapies. Key trends during this period include advancements in treatment methods, the introduction of new drug classes, collaboration between academic institutions, research organizations, and pharmaceutical companies, the adoption of new therapeutics, and developments in technology.

The growing adoption of gene therapy is expected to significantly boost the growth of the familial Mediterranean fever (FMF) pharmaceuticals market. Gene therapy is a medical approach that alters or replaces defective genes to treat or prevent diseases at the genetic level. The rise in gene therapy is fueled by advancements in genetic engineering, which allow for precise targeting and correction of genetic disorders, offering potential cures for conditions previously considered untreatable. In the case of familial Mediterranean fever (FMF), gene therapy targets the root cause mutations in the MEFV (Mediterranean fever) gene, potentially offering a long-term or permanent cure rather than merely managing symptoms. For example, in July 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, marking a 25% increase from the previous quarter. As a result, the rise in gene therapy is driving the growth of the FMF pharmaceuticals market.

Leading companies in the familial Mediterranean fever (FMF) pharmaceuticals market are focusing on developing advanced treatments, including cost-effective generic alternatives, as well as exploring novel biologics and gene therapies. A cost-effective generic alternative is a lower-cost version of a branded drug that retains the same active ingredients, dosage, safety, and effectiveness. For example, in January 2022, Camber Pharmaceuticals Inc., a US-based pharmaceutical manufacturing company, introduced generic Colcrys (colchicine) tablets, expanding its product portfolio. These tablets are used to treat and prevent FMF in both adults and children aged four and older, as well as for managing gout flare-ups. The tablets, available in 0.6 mg strength, come in 30- and 100-count bottles. This launch aligns with Camber's commitment to providing high-quality, affordable generic medications to improve patient care.

In January 2024, Swedish Orphan Biovitrum AB (Sobi), a Sweden-based manufacturer of Interleukin-1 inhibitors, entered into a partnership with Acino International AG. This partnership grants Acino the exclusive rights to distribute Sobi's specialized rare disease treatments in Kazakhstan, thereby expanding access to innovative therapies. Acino International AG, a Swiss-based pharmaceutical company, specializes in the development, manufacturing, and distribution of high-quality generic and specialty medicines.

Major players in the familial mediterranean fever pharmaceuticals market are Merck & Co. Inc., Bristol Myers Squibb, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Swedish Orphan Biovitrum AB (Sobi), Granules Pharmaceuticals Inc., Sanmar Group, Indena S.p.A., Harman Finochem, Camber Pharmaceuticals Inc., R-Pharm Group, Alchem International, AdvaCare Pharma USA LLC, ViennaLab Diagnostics GmbH, Honour Lab Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma.

Middle East was the largest region in the familial mediterranean fever pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in familial mediterranean fever pharmaceuticals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the familial mediterranean fever pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The familial mediterranean fever pharmaceuticals market consists of sales of NSAIDs, corticosteroids, immunosuppressants, disease-modifying antirheumatic drugs, and pain management medications used to manage inflammation and prevent complications in familial mediterranean fever patients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Familial Mediterranean Fever Pharmaceuticals Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on familial mediterranean fever pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for familial mediterranean fever pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The familial mediterranean fever pharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Colchicine; Interleukin-1 Inhibitors; Anti-IL-6 Drugs
• 2) By Route Of Administration: Oral; Injectable
• 3) By End Users: Hospitals; Clinical Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Colchicine: Oral Colchicine; Intravenous Colchicine
• 2) By Interleukin-1 Inhibitors: Anakinra; Canakinumab; Rilonacept
• 3) By Anti-IL-6 Drugs: Tocilizumab; Sarilumab; Siltuximab
• Companies Mentioned: Merck & Co. Inc.; Bristol Myers Squibb; Novartis International AG; Takeda Pharmaceutical Company Limited; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Familial Mediterranean Fever Pharmaceuticals Market Characteristics

3. Familial Mediterranean Fever Pharmaceuticals Market Trends And Strategies

4. Familial Mediterranean Fever Pharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Familial Mediterranean Fever Pharmaceuticals Growth Analysis And Strategic Analysis Framework

• 5.1. Global Familial Mediterranean Fever Pharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Familial Mediterranean Fever Pharmaceuticals Market Growth Rate Analysis
• 5.4. Global Familial Mediterranean Fever Pharmaceuticals Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Familial Mediterranean Fever Pharmaceuticals Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Familial Mediterranean Fever Pharmaceuticals Total Addressable Market (TAM)

6. Familial Mediterranean Fever Pharmaceuticals Market Segmentation

• 6.1. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colchicine
• Interleukin-1 Inhibitors
• Anti-IL-6 Drugs
• 6.2. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinical Diagnostic Laboratories
• Other End Users
• 6.4. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Colchicine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Colchicine
• Intravenous Colchicine
• 6.5. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Interleukin-1 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anakinra
• Canakinumab
• Rilonacept
• 6.6. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Anti-IL-6 Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tocilizumab
• Sarilumab
• Siltuximab

7. Familial Mediterranean Fever Pharmaceuticals Market Regional And Country Analysis

• 7.1. Global Familial Mediterranean Fever Pharmaceuticals Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Familial Mediterranean Fever Pharmaceuticals Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market

• 8.1. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Familial Mediterranean Fever Pharmaceuticals Market

• 9.1. China Familial Mediterranean Fever Pharmaceuticals Market Overview
• 9.2. China Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Familial Mediterranean Fever Pharmaceuticals Market

• 10.1. India Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Familial Mediterranean Fever Pharmaceuticals Market

• 11.1. Japan Familial Mediterranean Fever Pharmaceuticals Market Overview
• 11.2. Japan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Familial Mediterranean Fever Pharmaceuticals Market

• 12.1. Australia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Familial Mediterranean Fever Pharmaceuticals Market

• 13.1. Indonesia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Familial Mediterranean Fever Pharmaceuticals Market

• 14.1. South Korea Familial Mediterranean Fever Pharmaceuticals Market Overview
• 14.2. South Korea Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Familial Mediterranean Fever Pharmaceuticals Market

• 15.1. Western Europe Familial Mediterranean Fever Pharmaceuticals Market Overview
• 15.2. Western Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Familial Mediterranean Fever Pharmaceuticals Market

• 16.1. UK Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Familial Mediterranean Fever Pharmaceuticals Market

• 17.1. Germany Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Familial Mediterranean Fever Pharmaceuticals Market

• 18.1. France Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Familial Mediterranean Fever Pharmaceuticals Market

• 19.1. Italy Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Familial Mediterranean Fever Pharmaceuticals Market

• 20.1. Spain Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market

• 21.1. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market Overview
• 21.2. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Familial Mediterranean Fever Pharmaceuticals Market

• 22.1. Russia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Familial Mediterranean Fever Pharmaceuticals Market

• 23.1. North America Familial Mediterranean Fever Pharmaceuticals Market Overview
• 23.2. North America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Familial Mediterranean Fever Pharmaceuticals Market

• 24.1. USA Familial Mediterranean Fever Pharmaceuticals Market Overview
• 24.2. USA Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Familial Mediterranean Fever Pharmaceuticals Market

• 25.1. Canada Familial Mediterranean Fever Pharmaceuticals Market Overview
• 25.2. Canada Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Familial Mediterranean Fever Pharmaceuticals Market

• 26.1. South America Familial Mediterranean Fever Pharmaceuticals Market Overview
• 26.2. South America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Familial Mediterranean Fever Pharmaceuticals Market

• 27.1. Brazil Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Familial Mediterranean Fever Pharmaceuticals Market

• 28.1. Middle East Familial Mediterranean Fever Pharmaceuticals Market Overview
• 28.2. Middle East Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Familial Mediterranean Fever Pharmaceuticals Market

• 29.1. Africa Familial Mediterranean Fever Pharmaceuticals Market Overview
• 29.2. Africa Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Familial Mediterranean Fever Pharmaceuticals Market Competitive Landscape And Company Profiles

• 30.1. Familial Mediterranean Fever Pharmaceuticals Market Competitive Landscape
• 30.2. Familial Mediterranean Fever Pharmaceuticals Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Familial Mediterranean Fever Pharmaceuticals Market Other Major And Innovative Companies

• 31.1. Swedish Orphan Biovitrum AB (Sobi)
• 31.2. Granules Pharmaceuticals Inc.
• 31.3. Sanmar Group
• 31.4. Indena S.p.A.
• 31.5. Harman Finochem
• 31.6. Camber Pharmaceuticals Inc.
• 31.7. R-Pharm Group
• 31.8. Alchem International
• 31.9. AdvaCare Pharma USA LLC
• 31.10. ViennaLab Diagnostics GmbH
• 31.11. Honour Lab Ltd.
• 31.12. Vital Laboratories Pvt. Ltd.
• 31.13. Enomark Biotech Pvt. Ltd.
• 31.14. Gonane Pharma
• 31.15. Ennature Biopharma

32. Global Familial Mediterranean Fever Pharmaceuticals Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Familial Mediterranean Fever Pharmaceuticals Market

34. Recent Developments In The Familial Mediterranean Fever Pharmaceuticals Market

35. Familial Mediterranean Fever Pharmaceuticals Market High Potential Countries, Segments and Strategies

• 35.1 Familial Mediterranean Fever Pharmaceuticals Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Familial Mediterranean Fever Pharmaceuticals Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Familial Mediterranean Fever Pharmaceuticals Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34849_Familial_Mediterranean_Fever_Pharmaceuticals_GMR_2025